Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lee, Edwin
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial) Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial) Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial) Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2021 - Dec 2021 : Initiation of DREAMM-10 trial for 1L transplant ineligible multiple myeloma in combination with novel agent Dec 2020 - Dec 2020 : Data from DREAMM-8 trial for multiple myeloma at ASH 2020 More	Recruiting	3	357	Europe, Japan, US, RoW	Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib	GlaxoSmithKline	Multiple Myeloma	01/24	05/29
NCT04946383: Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging	Active, not recruiting	2	25	US	Dasatinib plus Quercetin	TruDiagnostic	Aging	12/21	06/22
NCT05389683: Effect of Personalized Elimination Diet on Food Sensitivity Related Symptoms	Completed	N/A	80	US	Elimination Diet	Vibrant America Clinical Lab	Food Sensitivity	02/24	02/24